Tumor-induced osteomalacia with elevated fibroblast growth factor 23: C case phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature

Chinese Journal of Cancer

Volumn 30, Issue 11, 2011, Pages 794-804

  Hu, Fang Ke ^a,b   Yuan, Fang ^a,c   Jiang, Cheng Ying ^b   Lv, Da Wei ^a   Mao, Bei Bei ^c   Zhang, Qiang ^a   Yuan, Zeng ^c   Wang, Yan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

^c INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Fibroblast growth factor 23 (FGF23); Hypophosphatemia; Phosphaturic mesenchymal tumors mixed connective tissue variants (PMTMCT); Tumor induced osteomalacia (TIO)

Indexed keywords

ALKALINE PHOSPHATASE; ANALGESIC AGENT; CALCITRIOL; CALCIUM CARBONATE; CORTICOSTEROID; CYANOCOBALAMIN; DIMETHYLAMINOMETHYLENEDIPHOSPHONATE TECHNETIUM TC 99M; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; LIVER PROTECTIVE AGENT; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; OSTEOCALCIN; PHOSPHATE; SALCATONIN;

ABNORMAL LABORATORY RESULT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASEPTIC NECROSIS; BLOOD SAMPLING; BONE PAIN; CANCER LOCALIZATION; CASE REPORT; CHONDRITIS; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE TUMOR; DISEASE COURSE; DISEASE EXACERBATION; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEMUR NECK FRACTURE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIP PAIN; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; MESENCHYMOMA; METABOLIC BONE DISEASE; METACARPAL BONE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; ONCOGENIC OSTEOMALACIA; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PHOSPHATURIC MESENCHYMAL TUMOR MIXED CONNECTIVE TISSUE VARIANT; POLYURIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; SPINAL PAIN; THIRST; THORAX RADIOGRAPHY; TUMOR SCINTISCANNING; WALKING DIFFICULTY;

BONE NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; HYPOPHOSPHATEMIA; MESENCHYMOMA; METACARPAL BONES; MIDDLE AGED; NEOPLASMS, CONNECTIVE TISSUE; OSTEOMALACIA; PHOSPHATES;

EID: 80355131365     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10013     Document Type: Article

References (37)

1. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature [J]. Am J Surg Pathol, 2004,28(1):1-30.
2. Econs MJ, Drezner MK. Tumor-in duced osteomalacia-unveiling a new hormone [J]. N Engl J Med, 1994,330 (23): 1679-1681.
3. Ramon I, Kleynen P, Body JJ, et al. Fibroblast growth factor 23 and its role in phosphate homeostasis [J]. Eur J Endocrinol, 2009,162(1):1-10.
4. Yoshioka K, Nagata R, Ueda M, et al. Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy [J]. Intern Med, 2006,45(20):1157-1160.
5. Nasu T, Kurisu S, Matsuno S, et al. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23 [J]. Intern Med, 2008,47(10):957-961.
6. Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia [J]. J Clin Endocrinol Metab, 2004,89(8):3979-3982.
7. Bahrami A, Weiss SW, Montgomery E, et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia [J]. Am J Surg Pathol, 2009,33(9): 1348-1354.
8. Liu S, Quarles LD. How fibroblast growth factor 23 works [J]. J Am Soc Nephrol, 2007,18(6):1637-1647.
9. Seijas R, Ares O, Sierra J, et al. Oncogenic osteomalacia: two case reports with surprisingly different outcomes [J]. Arch Orthop Trauma Surg, 2009,129(4):533-539.
10. Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue [J]. Auris Nasus Larynx, 2009,36(1):104-105.
11. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia [J]. Proc Natl Acad Sci U S A, 2001,98 (11):6500-6505.
12. Hannan FM, Athanasou NA, Teh J, et al. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1 [J]. Eur J Endocrinol, 2008,158(2):265-271.
13. Liu S, Vierthaler L, Tang W, et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23 [J]. J Am Soc Nephrol, 2008,19(12):2342-2350.
14. Gattineni J, Bates C, Twombley K, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1 [J]. Am J Physiol Renal Physiol, 2009,297(2):F282-F291.
15. Farrow EG, Davis SI, Summers LJ, et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule [J]. J Am Soc Nephrol, 2009,20(5):955-960.
16. De Beur SM, Finnegan RB, Vassiliadis J, et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism [J]. J Bone Miner Res, 2002,17(6):1102-1110.
17. Imel EA, Econs MJ. Fibroblast growth factor 23: Roles in health and disease [J]. J Am Soc Nephrol, 2005,16(9):2565-2575.
18. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets [J]. Cancer, 1987,59(8):1442-1454.
19. Seufert J, Ebert K, Muller J, et al. Octreotide therapy for tumor-induced osteomalacia [J]. N Engl J Med, 2001,345(26): 1883-1888.
20. Hesse E, Moessinger E, Rosenthal H, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography [J]. J Bone Miner Res, 2007,22(1):158-162.
21. Reubi JC, Waser B, Laissue JA, et al. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification [J]. Cancer Res, 1996,56 (8): 1922-1931.
22. Durham BH, Joseph F, Bailey LM, et al. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays [J]. Ann Clin Biochem, 2007,44(Pt 5):463-466.
23. Ogura E, Kageyama K, Fukumoto S, et al. Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23 [J]. Intern Med, 2008,47(7):637-641.
24. Schapira D, Ben Izhak O, Nachtigal A, et al. Tumor-induced osteomalacia [J]. Semin Arthritis Rheum, 1995,25(1):35-46.
25. Shields AT, Chesnut CH, 3rd. Diagnosis of postmenopausal osteoporosis: reviews in endocrine and metabolic disorders [J]. Rev Endocr Metab Disord, 2001,2(1):23-33.
26. Nakatani T, Sarraj B, Ohnishi M, et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (FGF23) - mediated regulation of systemic phosphate homeostasis [J]. FASEB J, 2009,23(2):433-441.
27. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism [J]. Curr Opin Nephrol Hypertens, 2006,15(4):437-441.
28. Kuro-o M. Klotho in chronic kidney disease-what's new? [J]. Nephrol Dial Transplant, 2009,24(6):1705-1708.
29. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1 (I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis [J]. Endocrinology, 2004,145(7):3087-3094.
30. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis [J]. J Bone Miner Res, 2004,19(3):429-435.
31. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is klotho an essential player? [J]. Am J Physiol Renal Physiol, 2009,296(3):F470-F476.
32. Perwad F, Zhang MY, Tenenhouse HS, et al. Fibroblast growth factor 23 impairs phosphorus and vitamin d metabolism in vivo and suppresses 25-hy droxyvitamin D-1a lpha+hy droxylase expression in vitro [J]. Am J Physiol Renal Physiol, 2007,293 (5):F1577-1583.
33. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D [J]. J Am Soc Nephrol, 2006,17(5):1305-1315.
34. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1alpha,25-di hydroxyvitamin D3 and phosphorus in vivo [J]. J Biol Chem, 2005,280(4):2543-2549.
35. Bikle D. Nonclassic actions of vitamin D [J]. J Clin Endocrinol Metab, 2009,94(1):26-34.
36. Yoshikawa S, Nakamura T, Takagi M, et al. Benign osteoblastoma as a cause of osteomalacia. A report of two cases [J]. J Bone Joint Surg Br, 1977,59(3):279-286.
37. Jacob JJ, Finny P, Thomas M, et al. Oncogenic osteomalacia [J]. J Assoc Physicians India, 2007,55: 231-233.